Elanco Animal Health vs Phibro Animal Health
ELAN and PAHC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELAN and PAHC compare
Elanco Animal Health is the larger company, worth 7.3 times as much as Phibro Animal Health ($11.5B against $1.6B).
Phibro Animal Health grew revenue faster over the last twelve months (17.1% versus 12.0% for Elanco Animal Health).
Phibro Animal Health keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −4.0% at Elanco Animal Health.
Phibro Animal Health pays a dividend yielding 1.2%; Elanco Animal Health does not pay one.
Phibro Animal Health scores higher on the StockData Score (22 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELAN | PAHC |
|---|---|---|
| Size and price | ||
| Market cap | $11.5B | $1.6B |
| Share price | $23.06 | $38.88 |
| Change, 1 year | 2.1% | −5.6% |
| Change, 5 years | −32.4% | 73.8% |
| Beta (5Y) | 1.11 | 0.73 |
| Employees | 9,400 | 2,605 |
| StockData Score | ||
| Total score | 9 | 22 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 3 | 6 (better) |
| Performance score | 3 | 6 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 16.0× |
| P/S | 2.3× | 1.0× (better) |
| P/B | 1.7× (better) | 4.1× |
| EV/EBITDA | 28.3× | 6.1× (better) |
| P/FCF | 30.4× (better) | 160× |
| PEG | – | 0.36 |
| FCF yield | 3.3% (better) | 0.62% |
| Fair value | $10.92 | $64.80 |
| Margin of safety | −111% | 40.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.0% | 17.1% (better) |
| Revenue growth, 5Y average | 7.6% | 12.7% (better) |
| Net income growth (TTM) | −146% | 107% (better) |
| EPS growth (TTM) | −149% | 104% (better) |
| EPS growth, 5Y average | – | 12.6% |
| Profitability | ||
| Gross margin | 55.4% (better) | 33.8% |
| Operating margin | – | 12.8% |
| Net margin | −4.0% | 6.6% (better) |
| FCF margin | 7.5% (better) | 0.65% |
| Return on equity | −3.0% | 29.7% (better) |
| Return on invested capital | – | 24.7% |
| Financial health | ||
| Debt / equity | 0.59 | – |
| Net debt / EBITDA | 6.43 | – |
| Interest coverage | – | 4.2× |
| Current ratio | 2.05 | 2.96 (better) |
| Altman Z-score | 1.32 | 3.11 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.2% |
| Payout ratio | – | 19.5% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Shareholder yield | 0.00% | 1.2% (better) |
| Ownership | ||
| Held by institutions | 113% | 51.8% |
| Held by insiders | 1.1% | 98.9% |
| Insider net buying, 12 months | $2.6M (better) | −$27.8M |
| Short interest, % of float | 7.5% | 234% |
Go deeper
- ELAN stock overview
- ELAN income statement
- ELAN valuation and score
- PAHC stock overview
- PAHC income statement
- PAHC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.